Across the major CVOTs SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), TECOS (sitagliptin), CARMELINA (linagliptin), and CAROLINA (linagliptin vs
The 8-year regulatory data exclusivity window expired on January 4, 2026, and a secondary injectable-formulation patent expired in March 2026
JACC Heart Fail 4:559566 Savarese G, Schrage B, Cosentino F, Lund LH, Rosano GMC, Seferovic P, Butler J (2020) Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
Patients can use this service to understand their treatment options better, including GLP1 medications, and discuss cost-saving strategies with licensed physicians available 24/7 across all 50 states.
Seidling, M
However, the medication does reduce appetite and may lower caloric intake, which could theoretically affect milk production if used while nursing